JP2013532146A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013532146A5 JP2013532146A5 JP2013514676A JP2013514676A JP2013532146A5 JP 2013532146 A5 JP2013532146 A5 JP 2013532146A5 JP 2013514676 A JP2013514676 A JP 2013514676A JP 2013514676 A JP2013514676 A JP 2013514676A JP 2013532146 A5 JP2013532146 A5 JP 2013532146A5
- Authority
- JP
- Japan
- Prior art keywords
- chromeno
- dihydro
- oxo
- pyrrol
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 34
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 229910052799 carbon Inorganic materials 0.000 claims 11
- 125000004432 carbon atom Chemical group C* 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 208000030159 metabolic disease Diseases 0.000 claims 8
- 229910052801 chlorine Inorganic materials 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 150000002148 esters Chemical class 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical group 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- -1 —CH 2 -aryl Chemical group 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 208000016097 disease of metabolism Diseases 0.000 claims 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000000034 thioazolyl group Chemical group 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 102000030595 Glucokinase Human genes 0.000 claims 2
- 108010021582 Glucokinase Proteins 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- YCPFQYGGDDPZBJ-ZDUSSCGKSA-N (2s)-2-(5,8-dimethoxy-3-oxo-1,9-dihydrochromeno[2,3-c]pyrrol-2-yl)-4-methylpentanoic acid Chemical compound C1C=2C(OC)=CC=C(OC)C=2OC2=C1CN([C@@H](CC(C)C)C(O)=O)C2=O YCPFQYGGDDPZBJ-ZDUSSCGKSA-N 0.000 claims 1
- ZGQKUSRLSNZSAZ-SFHVURJKSA-N (2s)-2-(5-chloro-3-oxo-1,9-dihydrochromeno[2,3-c]pyrrol-2-yl)-3-cyclohexyl-n-(1,3-thiazol-2-yl)propanamide Chemical compound C([C@H](N1C(=O)C2=C(C1)CC=1C=CC=C(C=1O2)Cl)C(=O)NC=1SC=CN=1)C1CCCCC1 ZGQKUSRLSNZSAZ-SFHVURJKSA-N 0.000 claims 1
- DDWDSGPCZOUOIV-FQEVSTJZSA-N (2s)-2-(5-chloro-3-oxo-1,9-dihydrochromeno[2,3-c]pyrrol-2-yl)-3-cyclohexyl-n-pyridin-2-ylpropanamide Chemical compound C([C@H](N1C(=O)C2=C(C1)CC=1C=CC=C(C=1O2)Cl)C(=O)NC=1N=CC=CC=1)C1CCCCC1 DDWDSGPCZOUOIV-FQEVSTJZSA-N 0.000 claims 1
- GAUIONMVLNGSKI-HNNXBMFYSA-N (2s)-2-(5-chloro-3-oxo-1,9-dihydrochromeno[2,3-c]pyrrol-2-yl)-4-methyl-n-(1,3-thiazol-2-yl)pentanamide Chemical compound O=C([C@@H](N1C(C2=C(CC3=CC=CC(Cl)=C3O2)C1)=O)CC(C)C)NC1=NC=CS1 GAUIONMVLNGSKI-HNNXBMFYSA-N 0.000 claims 1
- YWKFGOWRGVXVRX-KRWDZBQOSA-N (2s)-2-(5-chloro-3-oxo-1,9-dihydrochromeno[2,3-c]pyrrol-2-yl)-4-methyl-n-pyridin-2-ylpentanamide Chemical compound O=C([C@@H](N1C(C2=C(CC3=CC=CC(Cl)=C3O2)C1)=O)CC(C)C)NC1=CC=CC=N1 YWKFGOWRGVXVRX-KRWDZBQOSA-N 0.000 claims 1
- KODSXHNGZNXMHC-SFHVURJKSA-N (2s)-2-(8-chloro-3-oxo-1,9-dihydrochromeno[2,3-c]pyrrol-2-yl)-3-cyclohexyl-n-(1,3-thiazol-2-yl)propanamide Chemical compound C([C@H](N1CC2=C(C1=O)OC=1C=CC=C(C=1C2)Cl)C(=O)NC=1SC=CN=1)C1CCCCC1 KODSXHNGZNXMHC-SFHVURJKSA-N 0.000 claims 1
- WEEKKOREMIGRDV-FQEVSTJZSA-N (2s)-2-(8-chloro-3-oxo-1,9-dihydrochromeno[2,3-c]pyrrol-2-yl)-3-cyclohexyl-n-pyridin-2-ylpropanamide Chemical compound C([C@H](N1CC2=C(C1=O)OC=1C=CC=C(C=1C2)Cl)C(=O)NC=1N=CC=CC=1)C1CCCCC1 WEEKKOREMIGRDV-FQEVSTJZSA-N 0.000 claims 1
- GXNPIVLAMAOIGX-HNNXBMFYSA-N (2s)-2-(8-chloro-3-oxo-1,9-dihydrochromeno[2,3-c]pyrrol-2-yl)-4-methyl-n-(1,3-thiazol-2-yl)pentanamide Chemical compound O=C([C@@H](N1C(C2=C(CC3=C(Cl)C=CC=C3O2)C1)=O)CC(C)C)NC1=NC=CS1 GXNPIVLAMAOIGX-HNNXBMFYSA-N 0.000 claims 1
- FNNWHXSUOJRBJO-KRWDZBQOSA-N (2s)-2-(8-chloro-3-oxo-1,9-dihydrochromeno[2,3-c]pyrrol-2-yl)-4-methyl-n-pyridin-2-ylpentanamide Chemical compound O=C([C@@H](N1C(C2=C(CC3=C(Cl)C=CC=C3O2)C1)=O)CC(C)C)NC1=CC=CC=N1 FNNWHXSUOJRBJO-KRWDZBQOSA-N 0.000 claims 1
- ZFITUKKMKFQVOV-HNNXBMFYSA-N (2s)-2-(8-methoxy-3-oxo-1,9-dihydrochromeno[2,3-c]pyrrol-2-yl)-4-methyl-n-(1,3-thiazol-2-yl)pentanamide Chemical compound O=C([C@H](CC(C)C)N1CC2=C(C1=O)OC=1C=CC=C(C=1C2)OC)NC1=NC=CS1 ZFITUKKMKFQVOV-HNNXBMFYSA-N 0.000 claims 1
- XRHQBOSYMFERIZ-SFHVURJKSA-N (2s)-3-cyclohexyl-2-(5,8-dimethoxy-3-oxo-1,9-dihydrochromeno[2,3-c]pyrrol-2-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C([C@H](N1CC2=C(C1=O)OC=1C(OC)=CC=C(C=1C2)OC)C(=O)NC=1SC=CN=1)C1CCCCC1 XRHQBOSYMFERIZ-SFHVURJKSA-N 0.000 claims 1
- ZBTKODPNXRFMSF-FQEVSTJZSA-N (2s)-3-cyclohexyl-2-(5,8-dimethoxy-3-oxo-1,9-dihydrochromeno[2,3-c]pyrrol-2-yl)-n-pyridin-2-ylpropanamide Chemical compound C([C@H](N1CC2=C(C1=O)OC=1C(OC)=CC=C(C=1C2)OC)C(=O)NC=1N=CC=CC=1)C1CCCCC1 ZBTKODPNXRFMSF-FQEVSTJZSA-N 0.000 claims 1
- OREFYHQAZOLNIE-SFHVURJKSA-N (2s)-3-cyclohexyl-2-(8-methoxy-3-oxo-1,9-dihydrochromeno[2,3-c]pyrrol-2-yl)-n-(1,3-thiazol-2-yl)propanamide Chemical compound C([C@H](N1CC2=C(C1=O)OC=1C=CC=C(C=1C2)OC)C(=O)NC=1SC=CN=1)C1CCCCC1 OREFYHQAZOLNIE-SFHVURJKSA-N 0.000 claims 1
- UTYJLKOOXXNAFD-FQEVSTJZSA-N (2s)-3-cyclohexyl-2-(8-methoxy-3-oxo-1,9-dihydrochromeno[2,3-c]pyrrol-2-yl)-n-pyridin-2-ylpropanamide Chemical compound C([C@H](N1CC2=C(C1=O)OC=1C=CC=C(C=1C2)OC)C(=O)NC=1N=CC=CC=1)C1CCCCC1 UTYJLKOOXXNAFD-FQEVSTJZSA-N 0.000 claims 1
- UCLWFNCLGOWCAZ-CTNGQTDRSA-N (2s)-3-cyclohexyl-n-[1-[(2r)-2,3-dihydroxypropyl]pyrazol-3-yl]-2-(8-methoxy-3-oxo-1,9-dihydrochromeno[2,3-c]pyrrol-2-yl)propanamide Chemical compound C([C@H](N1CC2=C(C1=O)OC=1C=CC=C(C=1C2)OC)C(=O)NC1=NN(C[C@@H](O)CO)C=C1)C1CCCCC1 UCLWFNCLGOWCAZ-CTNGQTDRSA-N 0.000 claims 1
- CGSWQZWTNQZWNF-KRWDZBQOSA-N (2s)-n-(5-chloropyridin-2-yl)-2-(5,8-dimethoxy-3-oxo-1,9-dihydrochromeno[2,3-c]pyrrol-2-yl)-4-methylpentanamide Chemical compound O=C([C@H](CC(C)C)N1CC2=C(C1=O)OC=1C(OC)=CC=C(C=1C2)OC)NC1=CC=C(Cl)C=N1 CGSWQZWTNQZWNF-KRWDZBQOSA-N 0.000 claims 1
- QSWSHRPPPUYIDY-FQEVSTJZSA-N (2s)-n-(5-chloropyridin-2-yl)-3-cyclohexyl-2-(5,8-dimethoxy-3-oxo-1,9-dihydrochromeno[2,3-c]pyrrol-2-yl)propanamide Chemical compound C([C@H](N1CC2=C(C1=O)OC=1C(OC)=CC=C(C=1C2)OC)C(=O)NC=1N=CC(Cl)=CC=1)C1CCCCC1 QSWSHRPPPUYIDY-FQEVSTJZSA-N 0.000 claims 1
- SOGPQIDCJBQCHY-FQEVSTJZSA-N (2s)-n-(5-chloropyridin-2-yl)-3-cyclohexyl-2-(8-methoxy-3-oxo-1,9-dihydrochromeno[2,3-c]pyrrol-2-yl)propanamide Chemical compound C([C@H](N1CC2=C(C1=O)OC=1C=CC=C(C=1C2)OC)C(=O)NC=1N=CC(Cl)=CC=1)C1CCCCC1 SOGPQIDCJBQCHY-FQEVSTJZSA-N 0.000 claims 1
- BTGVPOVWLNJLLA-ZOWNYOTGSA-N ClC=1C=CC=NC1.ClC=1C=2CC3=C(C(N(C3)[C@H](C(=O)O)CC(C)C)=O)OC2C=CC1 Chemical compound ClC=1C=CC=NC1.ClC=1C=2CC3=C(C(N(C3)[C@H](C(=O)O)CC(C)C)=O)OC2C=CC1 BTGVPOVWLNJLLA-ZOWNYOTGSA-N 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- USWJTLZIOPWSHR-SFHVURJKSA-N methyl 6-[[(2s)-2-(5,8-dimethoxy-3-oxo-1,9-dihydrochromeno[2,3-c]pyrrol-2-yl)-4-methylpentanoyl]amino]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1NC(=O)[C@H](CC(C)C)N1C(=O)C(OC=2C(=C(OC)C=CC=2OC)C2)=C2C1 USWJTLZIOPWSHR-SFHVURJKSA-N 0.000 claims 1
- MPRPQSTVKHBSFO-SFHVURJKSA-N methyl 6-[[(2s)-2-(5-chloro-3-oxo-1,9-dihydrochromeno[2,3-c]pyrrol-2-yl)-4-methylpentanoyl]amino]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1NC(=O)[C@H](CC(C)C)N1C(=O)C(OC=2C(=CC=CC=2Cl)C2)=C2C1 MPRPQSTVKHBSFO-SFHVURJKSA-N 0.000 claims 1
- FWJOQFXGWHNWCK-SFHVURJKSA-N methyl 6-[[(2s)-2-(8-chloro-3-oxo-1,9-dihydrochromeno[2,3-c]pyrrol-2-yl)-4-methylpentanoyl]amino]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1NC(=O)[C@H](CC(C)C)N1C(=O)C(OC=2C(=C(Cl)C=CC=2)C2)=C2C1 FWJOQFXGWHNWCK-SFHVURJKSA-N 0.000 claims 1
- AUQLZCWIYJYNOE-SFHVURJKSA-N methyl 6-[[(2s)-2-(8-methoxy-3-oxo-1,9-dihydrochromeno[2,3-c]pyrrol-2-yl)-4-methylpentanoyl]amino]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1NC(=O)[C@H](CC(C)C)N1C(=O)C(OC=2C(=C(OC)C=CC=2)C2)=C2C1 AUQLZCWIYJYNOE-SFHVURJKSA-N 0.000 claims 1
- IKMJOSYSAQJYKR-NRFANRHFSA-N methyl 6-[[(2s)-3-cyclohexyl-2-(5,8-dimethoxy-3-oxo-1,9-dihydrochromeno[2,3-c]pyrrol-2-yl)propanoyl]amino]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1NC(=O)[C@@H](N1C(C2=C(CC3=C(OC)C=CC(OC)=C3O2)C1)=O)CC1CCCCC1 IKMJOSYSAQJYKR-NRFANRHFSA-N 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 0 Cc1ccc(*)c2c1OC(C(N(C1)C(C*)C(N*)=O)=O)=C1C2 Chemical compound Cc1ccc(*)c2c1OC(C(N(C1)C(C*)C(N*)=O)=O)=C1C2 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35561910P | 2010-06-17 | 2010-06-17 | |
| US61/355,619 | 2010-06-17 | ||
| PCT/EP2011/059783 WO2011157682A1 (en) | 2010-06-17 | 2011-06-14 | 3-oxo-3,9-dihydro-1h-chromeno[2,3-c]pyrroles as glucokinase activators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013532146A JP2013532146A (ja) | 2013-08-15 |
| JP2013532146A5 true JP2013532146A5 (enExample) | 2014-07-31 |
| JP5844355B2 JP5844355B2 (ja) | 2016-01-13 |
Family
ID=44266428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013514676A Expired - Fee Related JP5844355B2 (ja) | 2010-06-17 | 2011-06-14 | グルコキナーゼ活性剤としての３−オキソ−３，９−ジヒドロ−１Ｈ−クロメノ［２，３−ｃ］ピロール |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8178689B2 (enExample) |
| EP (1) | EP2582706A1 (enExample) |
| JP (1) | JP5844355B2 (enExample) |
| KR (1) | KR20130120993A (enExample) |
| CN (1) | CN102947311B (enExample) |
| BR (1) | BR112012032235A2 (enExample) |
| CA (1) | CA2801168A1 (enExample) |
| MX (1) | MX2012010668A (enExample) |
| RU (1) | RU2603191C2 (enExample) |
| WO (1) | WO2011157682A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2621725C2 (ru) * | 2012-12-25 | 2017-06-07 | Хуа Медисин | Способ получения 1-([1,3]диоксолан-4-илметил)-1н-пиразол-3-иламина |
| GB201714777D0 (en) | 2017-09-14 | 2017-11-01 | Univ London Queen Mary | Agent |
| WO2020083855A1 (en) * | 2018-10-24 | 2020-04-30 | F. Hoffmann-La Roche Ag | Novel tricyclic compounds for the treatment and prophylaxis of hepatitis b virus disease |
| CN113493442B (zh) * | 2020-04-03 | 2024-11-08 | 天津药物研究院有限公司 | 作为葡萄糖激酶活化剂的吡咯烷酮衍生物及其制备方法和用途 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK496784A (da) | 1983-10-18 | 1985-04-19 | Du Pont | 8-substituerede pyrazolopentathiepiner og dermed beslaegtede forbindelser |
| JPS6284064A (ja) | 1985-10-09 | 1987-04-17 | Shionogi & Co Ltd | ３−パ−フルオロアルキル−５−ヒドロキシイソオキサゾ−ル類 |
| JPH0477477A (ja) | 1990-07-18 | 1992-03-11 | Takeda Chem Ind Ltd | チアジアゾール酢酸誘導体の製造法 |
| GB9103454D0 (en) | 1991-02-19 | 1991-04-03 | Pfizer Ltd | Therapeutic agents |
| IL116507A (en) | 1991-11-13 | 1997-08-14 | Schering Ag | Pyrazole derivatives |
| US5498190A (en) | 1994-06-27 | 1996-03-12 | Handsontoys, Inc. | Flexible foam construction toy and method of manufacturing same |
| JPH08151386A (ja) | 1994-09-27 | 1996-06-11 | Takeda Chem Ind Ltd | 複素環エチルチオセフェム化合物、その製造法および抗菌組成物 |
| ES2205760T3 (es) | 1998-04-30 | 2004-05-01 | Agouron Pharmaceuticals, Inc. | Compuestos antipicornavirales, su preparacion y su utilizacion. |
| GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
| US6610846B1 (en) | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
| JP2003505384A (ja) | 1999-07-15 | 2003-02-12 | ファーマコピーア，インコーポレーティッド | ブラジキニンｂ１受容体アンタゴニスト |
| US7329679B2 (en) | 2000-01-27 | 2008-02-12 | Schering Aktiengesellschaft | 1,2 Diarylbenzimidazoles and their pharmaceutical use |
| ATE280163T1 (de) | 2000-05-08 | 2004-11-15 | Hoffmann La Roche | Substituierte phenylacetamide und ihre verwendung als glukokinase aktivatoren |
| US6482951B2 (en) * | 2000-12-13 | 2002-11-19 | Hoffmann-La Roche Inc. | Isoindolin-1-one glucokinase activators |
| GB0112834D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| AU2003232204B8 (en) | 2002-04-26 | 2009-07-30 | F. Hoffmann-La Roche Ag | Substituted phenylacetamides and their use as glucokinase activators |
| EP1531815B1 (en) | 2002-06-27 | 2014-09-24 | Novo Nordisk A/S | Glucokinase activators |
| AU2003287038A1 (en) | 2002-10-09 | 2004-05-04 | The Board Of Trustees Of The University Of Illinois | METHOD OF PREPARING (3R, 3aS, 6aR) -3- HYDROXYHEXAHYDROFURO (2, 3-b) FURAN AND RELATED COMPOUNDS |
| PE20040801A1 (es) | 2002-12-12 | 2004-11-25 | Hoffmann La Roche | Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa |
| PL378117A1 (pl) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| WO2004081001A1 (ja) | 2003-02-13 | 2004-09-23 | Banyu Pharmaceutical Co., Ltd. | 新規２－ピリジンカルボキサミド誘導体 |
| WO2004076420A1 (ja) | 2003-02-26 | 2004-09-10 | Banyu Pharmaceutical Co., Ltd. | ヘテロアリールカルバモイルベンゼン誘導体 |
| CA2547591C (en) | 2003-10-24 | 2010-08-17 | Aventis Pharmaceuticals Inc. | Novel compounds and compositions as cathepsin inhibitors |
| EP1682135B1 (en) | 2003-10-27 | 2011-07-27 | Merck Sharp & Dohme Corp. | salt of a tetrahydropyranyl cyclopentyl tetrahydropyridopyridine derivative as CCR2-antagonist |
| DK1723128T3 (da) | 2004-01-06 | 2013-02-18 | Novo Nordisk As | Heteroarylurinstoffer og deres anvendelse som glucokinaseaktivatorer |
| CA2554686A1 (en) | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Compounds |
| WO2005090291A1 (en) | 2004-03-16 | 2005-09-29 | Wyeth | Ion channel modulators |
| US7687502B2 (en) | 2004-03-23 | 2010-03-30 | Banyu Pharmaceutical Co., Ltd. | Substituted quinazoline or pyridopyrimidine derivative |
| TW200600086A (en) | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
| KR100672184B1 (ko) * | 2004-09-21 | 2007-01-19 | 주식회사종근당 | 파록세틴의 콜린산 또는 콜린산 유도체 염 |
| WO2006058923A1 (en) | 2004-12-03 | 2006-06-08 | Novo Nordisk A/S | Heteroaromatic glucokinase activators |
| WO2006064286A1 (en) | 2004-12-13 | 2006-06-22 | Medivir Uk Ltd | Cathepsin s inhibitors |
| WO2007006760A1 (en) | 2005-07-08 | 2007-01-18 | Novo Nordisk A/S | Dicycloalkyl urea glucokinase activators |
| TWI359149B (en) | 2005-07-11 | 2012-03-01 | Mitsubishi Tanabe Pharma Corp | An oxime derivative and preparations thereof |
| RU2443691C2 (ru) | 2005-07-14 | 2012-02-27 | Транстех Фарма, Инк. | Мочевинные активаторы глюкокиназы |
| JPWO2007026761A1 (ja) | 2005-08-31 | 2009-03-12 | アステラス製薬株式会社 | チアゾール誘導体 |
| GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| US8796313B2 (en) | 2005-11-01 | 2014-08-05 | Janssen Pharmaceutica N.V. | Substituted dihydroisoindolones as allosteric modulators of glucokinase |
| TWI411607B (zh) | 2005-11-14 | 2013-10-11 | Vitae Pharmaceuticals Inc | 天門冬胺酸蛋白酶抑制劑 |
| US20070197532A1 (en) | 2005-11-18 | 2007-08-23 | Cao Sheldon X | Glucokinase activators |
| JP5236499B2 (ja) | 2006-01-27 | 2013-07-17 | アレイ バイオファーマ、インコーポレイテッド | グルコキナーゼ活性化剤 |
| AU2007235558B2 (en) | 2006-03-24 | 2011-12-01 | Array Biopharma Inc. | 2 -aminopyridine analogs as glucokinase activators |
| WO2007115968A2 (en) | 2006-04-12 | 2007-10-18 | F. Hoffmann-La Roche Ag | Process for the preparation of a glucokinase activator |
| PL2463283T3 (pl) | 2006-04-20 | 2014-10-31 | Pfizer Prod Inc | Skondensowane fenyloamidowe związki heterocykliczne do zapobiegania i leczenia chorób pośredniczonych przez glukokinazę |
| US7880012B2 (en) | 2006-04-28 | 2011-02-01 | Transtech Pharma, Inc. | Benzamide glucokinase activators |
| JP5386350B2 (ja) | 2006-05-31 | 2014-01-15 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体 |
| CN101490064B (zh) * | 2006-07-06 | 2012-10-10 | 百时美施贵宝公司 | 新颖葡萄糖激酶活化剂及其使用方法 |
| US7888504B2 (en) | 2006-07-06 | 2011-02-15 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
| US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| EP2261216A3 (en) | 2006-07-24 | 2011-12-14 | F. Hoffmann-La Roche AG | Pyrazoles as glucokinase activators |
| EP2116533B1 (en) | 2007-03-07 | 2013-07-10 | Kyorin Pharmaceutical Co., Ltd. | Glucokinase activator |
| WO2008121602A1 (en) | 2007-03-29 | 2008-10-09 | Smithkline Beecham Corporation | Chemical compounds |
| US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
-
2011
- 2011-06-09 US US13/156,394 patent/US8178689B2/en not_active Expired - Fee Related
- 2011-06-14 KR KR1020127032727A patent/KR20130120993A/ko not_active Ceased
- 2011-06-14 EP EP11726127.1A patent/EP2582706A1/en not_active Withdrawn
- 2011-06-14 CN CN201180029732.8A patent/CN102947311B/zh not_active Expired - Fee Related
- 2011-06-14 BR BR112012032235A patent/BR112012032235A2/pt not_active IP Right Cessation
- 2011-06-14 CA CA2801168A patent/CA2801168A1/en not_active Abandoned
- 2011-06-14 RU RU2012156706/04A patent/RU2603191C2/ru not_active IP Right Cessation
- 2011-06-14 JP JP2013514676A patent/JP5844355B2/ja not_active Expired - Fee Related
- 2011-06-14 WO PCT/EP2011/059783 patent/WO2011157682A1/en not_active Ceased
- 2011-06-14 MX MX2012010668A patent/MX2012010668A/es active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012532112A5 (enExample) | ||
| JP2017533968A5 (enExample) | ||
| JP2014506907A5 (enExample) | ||
| JP2019505541A5 (enExample) | ||
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| JP2014037426A5 (enExample) | ||
| JP2014526549A5 (enExample) | ||
| JP2014507455A5 (enExample) | ||
| JP2017511794A5 (enExample) | ||
| RU2012103487A (ru) | Ингибирующие jak соединения на основе пиразолопиримидина и способы | |
| JP2013515074A5 (enExample) | ||
| JP2017538773A5 (enExample) | ||
| JP2008513516A5 (enExample) | ||
| JP2014518853A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2008513498A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2011512412A5 (enExample) | ||
| JP2013542267A5 (enExample) | ||
| JP2017538689A5 (enExample) | ||
| JP2015536997A5 (enExample) | ||
| JP2016508135A5 (enExample) | ||
| JP2010527985A5 (enExample) | ||
| JP2011517697A5 (enExample) |